1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment
Open Access
- 1 October 2006
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 42 (15) , 2499-2503
- https://doi.org/10.1016/j.ejca.2006.05.021
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomasNeurology, 2004
- Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p DeletionsJournal of Clinical Oncology, 2004
- Chemotherapy of anaplastic oligodendroglial tumoursExpert Opinion on Pharmacotherapy, 2004
- Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomasAnnals of Oncology, 2003
- Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971Journal of Clinical Oncology, 2003
- Chromosomal anomalies in oligodendroglial tumors are correlated with clinical featuresCancer, 2003
- Impact of Chromosome 1p Status in Response of Oligodendroglioma to Temozolomide: Preliminary ResultsJournal of Neuro-Oncology, 2003
- Safety and Efficacy of Temozolomide in Patients With Recurrent Anaplastic Oligodendrogliomas After Standard Radiotherapy and ChemotherapyJournal of Clinical Oncology, 2001
- Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic OligodendrogliomasJNCI Journal of the National Cancer Institute, 1998
- Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1994